GLP1R and type 2 diabetes mellitus: Complementary evidence comes from SURPASS‐CVOT, an event‐driven cardiovascular outcomes trial in > 13,000 patients with type 2 diabetes and established atherosclerotic cardiovascular disease, which compared tirzepatide (up to 15 mg weekly) with dulaglutide 1.5 mg weekly, a GLP‐1 receptor agonist with proven CV benefit [9].